Verrica Pharmaceuticals Inc.
Income Statement
| Line Item | FY2018 | FY2017 |
|---|---|---|
| Revenue | — | — |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | $12.8M | $3.7M |
| SG&A Expense | $9.1M | $727.0K |
| Operating Income | $-21.9M | $-4.5M |
| Operating Margin | — | — |
| Interest Expense | — | — |
| Pretax Income | — | — |
| Income Tax Expense | — | — |
| Net Income | $-20.6M | $-4.5M |
| Net Margin | — | — |
| EPS (Basic) | $-0.71 | $-0.78 |
| EPS (Diluted) | $-0.71 | $-0.78 |
| Shares Outstanding (Basic) | 51.4M | 7.4M |
| Shares Outstanding (Diluted) | 51.4M | 7.4M |
| Dividends Per Share | — | — |